VCM
MYGN icon

Valiant Capital Management’s Myriad Genetics MYGN Stock Holding History

Valiant Capital Management’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-272,000
Closed -$10.2M – 23
2015
Q3 		$10.2M Hold
272,000
– – 0.7% 19
2015
Q2 		$9.24M Hold
272,000
– – 0.86% 18
2015
Q1 		$9.63M Hold
272,000
– – 0.92% 16
2014
Q4 		$9.26M Buy
+272,000
New +$9.65M 0.99% 15

Other funds holding MYGN

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Valiant Capital Management's MYGN Position: Q4 2015 in Review

Valiant Capital Management sold out of Myriad Genetics (MYGN) in Q4 2015, closing a stake of 272,000 shares — an estimated $10.2M sold.

Valiant Capital Management first reported a position in MYGN in Q4 2014 and held it in 4 quarters. The position peaked at $10.2M in Q3 2015. 232 funds tracked by Wall St. Rank hold MYGN as of Q4 2015.

  • Valiant Capital Management reported no remaining Myriad Genetics position as of Q4 2015 after selling out during the quarter.
  • Valiant Capital Management sold 272,000 Myriad Genetics shares in Q4 2015, an estimated $10.2M.
  • Valiant Capital Management first reported a position in Myriad Genetics in Q4 2014 and held it in 4 quarters.
  • Valiant Capital Management's Myriad Genetics position peaked at $10.2M in Q3 2015.
  • 232 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2015.

Based on Valiant Capital Management's 13F filing for Q4 2015, filed 11 Feb 2016.